| Literature DB >> 32055727 |
Bukola Adebayo-Tayo1, Racheal Fashogbon1.
Abstract
Biological evaluation of exopolysaccharides (EPS) produced by wild type and mutant Lactobacillus delbureckii (EPSWLD and EPSMLD) was investigated. Varying degrees of functional groups associated with polysaccharides were present thus confirming the EPS. The EPSs had strong antioxidant potential in a dose dependent (0.5-10 mg/mL) manner. EPSWLD and EPSMLD exhibited the highest 1,1-diphemy 1-2-picryl-hydrazyl (DPPH) activity (73.4 % and 65.6 %), total antioxidant activity (1.80 % and 1.42 %), H2O2 scavenging activity (88.5 % and 78.6 %) and Ferric Reducing Antioxidant Power (FRAP) (1.89 % and1.81 %) at 10 mg/mL respectively. WLD and MLD were highly susceptible to chloramphenicol, cotrimoxazole, tetracycline, erythromycin and ceftazidine and resistant to cefuroxime, gentamicin and cloxacillin. The EPSs had antibacterial activity against the test pathogens. B. subtilis and S. aureus had the highest susceptibility (26.0 mm and 23.0 mm). EPSMLD modulate the highest IgG, IgA and IgM production (68-126 mg/dL and 67-98 mg/dL and 64-97 mg/dL) in the treated tumor induced mice (TTIM). EPSWLD and EPSMLD exhibited reduction capability on the CEA level (3.99-4.35 ng/L and 4.12-4.23 ng/L) of the TTIM. EPSWLD TTIM had the highest amount of RBC, WBC and PCV (5.6 × 1012%, 68000% and 42%). The EPS increased the lifespan of TTIM. In conclusion EPSWLD and EPSMLD had strong biological potential with pharmacological and neutraceutical activity.Entities:
Keywords: Antimicrobial potential; Antioxidants activity; Exopolysaccharides; Hematological; Immune system; Microbiology
Year: 2020 PMID: 32055727 PMCID: PMC7005431 DOI: 10.1016/j.heliyon.2020.e03268
Source DB: PubMed Journal: Heliyon ISSN: 2405-8440
Figure 1Production of EPS by the wild and mutant Lactobacillus delbrueckii.
Figure 2a–b: FTIR spectrum of (a) EPSWLD and (b) EPSMLD.
Distribution of functional group of the FTIR spectra of EPSWLD and EPSMLD.
| S/N | Peak (cm−1) | Functional group | EPSWLD | EPSMLD |
|---|---|---|---|---|
| 1 | 453.29 | Chloroalkanes | + | + |
| 2 | 524.66. 549.73, 551.66 | Alkyl halide | + | + |
| 3 | 619.17, 621.1 | Alkynes | + | + |
| 4 | 702.11, 761.91 | Alkanes | + | + |
| 5 | 839.06, 866.07 | Alkyl halide | + | + |
| 6 | 908.5 | Aromatics | + | + |
| 7 | 1020.38, 1049.31 | Alkenes | + | + |
| 8 | 1101.39, 1103.32 | Alkenes | + | + |
| 9 | 1153.41 | Alkenes | + | + |
| 10 | 1274.99 | Alkanes | + | - |
| 11 | 1236.41 | Aliphatic amines | - | + |
| 12 | 1363.72, 1273.06 | Alkanes | + | + |
| 13 | 1419.66, 1415.8 | Ester | + | + |
| 14 | 1637.62, 1641.48 | Un-Saturated Ester | + | + |
| 15 | 1658 | Amide | + | - |
| 16 | 2061.96 | Alcohol | + | + |
| 17 | 2364.81, 2360.95 | Alcohol | + | + |
| 18 | 2928.04, 2929.97 | Aldehyde | + | - |
| 19 | 3404.47, 3385.18 | Hydroxyl/alcohol | + | + |
Sugar concentration and monosaccharide composition of the EPSWLD and EPSMLD.
| Monosaccharide Name | EPSWLD | EPSMLD | ||||
|---|---|---|---|---|---|---|
| Retention time | Area under Curve | Amount (mg/100g) | Retention time | Area under curve | Amount (mg/100g) | |
| Ribose | 8.656h | 1.62f | 2.06638f | 8.92h | 5.71c | 1.48119h |
| Xylose | 10.842g | 6.19b | 4.47902d | 10.65g | 4.43d | 1.82028g |
| Arabinose | 12.266f | 1.22g | 3.23573e | 12.27f | 4.46d | 2.25737f |
| Rhamnose | 13.660e | 1.06h | 3.55212e | 13.66e | 2.82e | 6.10709e |
| Fructose | 14.695d | 5.81c | 9.58819c | 14.69d | 8.10a | 7.73321d |
| Glucose | 16.094c | 1.93e | 39.8584a | 16.04c | 1.34f | 12.86967b |
| Mannose | 17.094b | 4.81d | 9.50729c | 17.09b | 7.16b | 8.70846c |
| Galactose | 18.056a | 6.50a | 20.44084b | 18.06a | 1.17g | 23.85038a |
Mean of values with the same superscript are not significantly different (P ≤ 0.05).
Antioxidant potential of the EPSWLD and EPSMLD.
| Conc. (mg/L) | DPPH (%) | Total Antioxidant Capacity (%) | H2O2 (%) | FRAP (%) | ||||
|---|---|---|---|---|---|---|---|---|
| EPSWLD | EPSMLD | EPSWLD | EPSMLD | EPSWLD | EPSMLD | EPSWLD | EPSMLD | |
| 0.5 | 38.5e | 37.5e | 1.21e | 0.41e | 50.6e | 33.1e | 1.23e | 1.00e |
| 1.0 | 42.5d | 46.3d | 1.47d | 0.71d | 70.8d | 57.8d | 1.68d | 1.04d |
| 2.5 | 59.4c | 53.3c | 1.64c | 0.82c | 80.7c | 64.2c | 1.75c | 1.26c |
| 5.0 | 68.6b | 64.6b | 1.75b | 0.87b | 81.0b | 65.7b | 1.86b | 1.72b |
| 10 | 73.4a | 65.6a | 1.80a | 1.42a | 88.5a | 78.6a | 1.89a | 1.81a |
| Ascorbic acid (10 mg/L) | 27.9f | 30.8f | 0.87f | 0.25f | 37.9f | 21.8f | 0.59f | 0.66f |
Mean of values with the same superscript on the same column are not significantly different (P ≤ 0.05).
Sensitivity test of the WLD and MLD to some antibiotics.
| Antibiotics | Zone of Inhibition (mm) | |
|---|---|---|
| WLD | MLD | |
| Ceftazidine (30μg) | 26 | 20 |
| Cefuroxime(30μg) | 0 | 0 |
| Gentamicine (10μg) | 0 | 0 |
| Cefixime (5μg) | 18 | 14 |
| Ofloxacin (5μg) | 22 | 20 |
| Augmentin (30μg) | 24 | 20 |
| Nitrofurantoin (300μg) | 14 | 8 |
| Ciprofloxacine (5μg) | 22 | 16 |
| Amoxycillin (25μg) | 18 | 14 |
| Erythromycin (5μg) | 28 | 22 |
| Tetracycline (10μg) | 26 | 24 |
| Cloxacillin (5μg) | 0 | 0 |
| Cotrimoxazole (25μg) | 24 | 20 |
| Chloramphenicol (30μg) | 26 | 24 |
Figure 3Antibacterial activity of EPSWLD and EPSMLD against some test pathogens.
Antitumor and Immunomodulatory potential of EPSWLD and EPSMLD.
| Groups | Cigarrete | EPSWLD | EPSMLD | % Flurouracil | Immunoglobulins (mg/dL) | ||
|---|---|---|---|---|---|---|---|
| IgG | IgA | IgM | |||||
| Grp 1 | - | - | - | - | 68 | 67 | 64 |
| Grp 2 | + | - | - | - | 105 | 67 | 63 |
| Grp 3 | + | - | - | + | 108 | 84 | 70 |
| Grp 4 | + | + | - | - | 122 | 95 | 89 |
| Grp 5 | + | - | + | - | 126 | 98 | 97 |
Key: Florouracil is a standard drug for cancer treatment.
Carcinoembryonic antigen (CEA) of the untreated and treated tumor induced mice.
| Group | Treatments | CEA |
|---|---|---|
| 1 | CNT 1 | 0.01 |
| CNT 2 | 0.00 | |
| CNT 3 | 0.00 | |
| CNT 4 | 0.00 | |
| 2 | CNT+1 | 6.41 |
| CNT+2 | 6.29 | |
| CNT+3 | 6.42 | |
| 3 | 5F1 | 4.79 |
| 5F2 | 4.97 | |
| 5F3 | 5.02 | |
| 4 | EPSWLD01 | 4.35 |
| EPSWLD02 | 4.06 | |
| EPSWLD03 | 3.99 | |
| EPSWLD04 | 4.11 | |
| 5 | EPSMLD01 | 4.23 |
| EPSMLD02 | 4.19 | |
| EPSMLD03 | 4.17 | |
| EPSMLD04 | 4.12 |
Figure 4Life span of the untreated and treated tumor induced mice; Group 1 (non-tumor induced mice and untreated); Group 2 (tumor induced mice that is not treated); Group 3 (tumor induced mice treated with 5-fluorouracil acid); Group 4 (tumor induced mice treated with EPSWLD) and Group 5 (tumor induced mice treated with EPSMLD).
Hematology Parameters of the untreated and treated mice.
| Hematology parameters | Group 1 (c1) | Group 2 (c2) | Group 3 (c3) | Group 4 | Group 5 |
|---|---|---|---|---|---|
| RBCx1012 | 4.7b | 3.0d | 3.7c | 5.6a | 3.8c |
| WBC | 37000c | 52000b | 65000a | 68000a | 51000b |
| Platelet | 21700b | 23400a | 15500c | 21300b | 11000d |
| Lymph | 70b | 42g | 53c | 77a | 70b |
| Neut | 70b | 58d | 61c | 72a | 64c |
| PCV (%) | 39.0b | 17.0d | 29.0c | 42.0a | 27c |
| HB d/dl | 12.9b | 5.66d | 9.68c | 13.1a | 10.67b |
| MCH | 2.74a | 1.89d | 2.61b | 2.34c | 2.80a |
| MCHC | 33.07b | 33.3b | 33.4b | 31.1c | 39.5a |
| MCV | 84.2a | 56.7d | 78.3b | 82.5a | 68.4c |
Mean of values with the same superscript are not significantly different (P ≤ 0.05).
Figure 5(a–e): Photomicrograph of the liver section of (a) non-tumor induced mice and untreated; (b) mice induced tumor and not treated; (c) tumor induced mice treated with 5-fluorouracil acid; (d) tumor induced mice treated with EPSWLD and (e) tumor induced mice treated with EPSMLD.
Figure 6(a–e): Photomicrograph of the lung section of (a) non-tumor induced mice and untreated; (b) mice induced tumor and not treated; (c) tumor induced mice treated with 5-fluorouracil acid; (d) tumor induced mice treated with EPSWLD and (e) tumor induced mice treated with EPSMLD.